Skip to main content
Premium Trial:

Request an Annual Quote

Mass Gen Begins Study on Depression Treatment Response Using Genetic Biomarker Data

NEW YORK (GenomeWeb News) – The Massachusetts General Hospital is starting a major study aimed at guiding treatment of patients suffering from treatment-resistant major depressive disorder.

The study, which is using genetic biomarker data to compare standard treatment with assay-guided treatment in inpatient adults with treatment-resistant depression, will use Genomind's Genecept Assay. The technology combines a proprietary panel of genetic tests with an analytical report to clinicians.

The primary objective of the study is to improve depressive symptoms from baseline to six months, Genomind said. Other goals are to change clinician behavior and reduce costs.

Researchers will focus on pharmacogenetic genotyping of metabolic activity, which can then be used to guide treatment of patients with antidepressants. Also, genome-wide association study analysis will be performed in the future to identify biomarkers that may be predictive of patient response to and tolerance of certain therapeutics.

Recruitment of patients begins immediately.

Based in Chalfont, Penn., Genomind specializes in neuropsychiatric personalized medicine using genetic information.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.